Fuld + Company

Fuld + Company
Fuld + Company
Blog Post
  • The Wall Street Journal and other sources revealed yesterday that pharmacy operator CVS Health Corporation has made an offer to acquire No. 3 health insurer Aetna Inc.  Wouldn’t it have been rewarding to have known the probability of such an acquisition? Wouldn’t the executives at Walgreens, Express Scripts, or United Health Group and Anthem have benefited from an evaluation that showe...

Fuld + Company
Fuld + Company
Blog Post
  • Clinical development has historically been a laborious and expensive process, driven by lengthy patient recruitment timelines, increasingly complex study designs, and high procedural costs, across different therapeutic areas. Additionally, a complex and dynamic regulatory framework has made it difficult to introduce new technologies to facilitate the development process. 

Fuld + Company
Fuld + Company
Blog Post
  • To the casual observer, it may seem as if Tesla will be the end-all be-all for our future transportation needs. The reveal of the market-priced Model 3 earlier this year has led some to ring the victory bell, announcing Tesla as the unheralded king of electronic transportation. Not only will it be providing your residential vehicles, it will also be tackling the commercial and public t...

Fuld + Company
Fuld + Company
Blog Post
  • The recent launch of Tesla’s mass-market vehicle, the Model 3, has people wondering what the connected car landscape will look like in the future. Tesla projects exponential sales growth, vastly exceeding current production capabilities. While Tesla is at the forefront of the headlines,other automobile manufactures, entertainment platform companies, data management companies, software ...

Fuld + Company
Fuld + Company
Blog Post
  • With less than three years until the re-evaluation of HealthyPeople2020 Immunization targets, Benjamin Blumi, Senior Vice President of the American Pharmacists Association (APhA) Foundation, and his colleagues reported a dramatic breakthrough: in a study run from the fall of 2016 through spring of 2016, the number of pharmacist-administered adult vaccinations increased by more than 40 ...

Fuld + Company
Fuld + Company
Blog Post
  • Drug pricing became a topic of common and passionate interest in 2015 when Martin Shkreli, then CEO of Turing Pharmaceuticals, dramatically increased the price of a single Daraprim tablet - from $13.50 to $750.00, the price of an average lunch to that of a large household appliance. The interest intensified in 2016, when Mylan increased the cost of the EpiPen by 400 percent. Public out...

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

By signing up, you agree to the Terms of Service and Privacy Policy.

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in

By signing up, you agree to the Terms of Service and Privacy Policy.